NEW YORK, November 23, 2016 /PRNewswire/ --
In today's pre-market research, Stock-Callers.com follows the performances of Wright Medical Group N.V. (NASDAQ: WMGI), Varian Medical Systems Inc. (NYSE: VAR), MiMedx Group Inc. (NASDAQ: MDXG), and WaferGen Bio-systems Inc. (NASDAQ: WGBS). These companies belong to the Healthcare sector, which finished slightly above its session lows on Tuesday, November 22, 2016. As per an article on the NASDAQ, the NYSE Health Care Index fell 1.7%, while shares of health care companies in the S&P 500 dropped more than 1.5% as a group. Register now and get full and free access to our downloadable research reports on these stocks at:
Wright Medical Group
Amsterdam, the Netherlands headquartered Wright Medical Group N.V.'s stock finished Tuesday's session 1.86% lower at $23.19 with a total trading volume of 512,046 shares. Shares of the Company, which designs, manufactures, markets, and sells orthopedic products in the US, Europe, and internationally, are trading 13.29% above their 200-day moving average. The stock has a Relative Strength Index (RSI) of 51.59.
On November 02nd, 2016, Wright Medical announced that on November 1st, 2016, its wholly owned subsidiary Wright Medical Technology, Inc. entered into a Master Settlement Agreement (MSA) with Court-appointed attorneys representing plaintiffs in the previously disclosed metal-on-metal hip multi-district litigation known as In Re: Wright Medical Technology, Inc., CONSERVE® Hip Implant Products Liability Litigation, MDL No. 2329 (MDL). Under the terms of the MSA, the parties agreed to settle 1,292 specifically identified CONSERVE, DYNASTY or LINEAGE revision claims which meet the eligibility requirements of the MSA and are either pending in the MDL or JCCP, or are subject to tolling agreements approved in the MDL or JCCP, for a total settlement amount of $240 million. Access our complete research report on WMGI for free at:
Varian Medical Systems
On Tuesday, shares in Palo Alto, California headquartered Varian Medical Systems Inc. recorded a trading volume of 637,667 shares. The stock ended the session 0.37% higher at $89.99. The Company's shares have advanced 11.37% on an YTD basis. The stock is trading 3.28% above its 200-day moving average. Moreover, shares of Varian Medical Systems, which designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide, have an RSI of 45.17.
On November 21st, 2016, Varian Medical Systems announced that its board of directors has authorized the company to repurchase an additional 8 million shares of its common stock, commencing on January 1st, 2017. The company has 4 million shares remaining in an existing 8 million share repurchase authorization that ends on December 31st, 2016. The complimentary research report on VAR can be downloaded at:
Shares in Marietta, Georgia headquartered MiMedx Group Inc. closed the day 0.51% lower at $9.79. The stock recorded a trading volume of 450,566 shares. The Company's shares have gained 13.44% in the last month, 35.22% in the previous three months, and 4.48% on an YTD basis. The stock is trading 11.06% above its 50-day moving average and 20.86% above its 200-day moving average. Additionally, shares of MiMedx, which develops, processes, and markets patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues, and human skin and bone, have an RSI of 63.44.
On November 03rd, 2016, MiMedx announced that with the online publication of USP 40 - NF 35, its dehydrated human amnion/chorion membrane (dHACM) allografts will now be recognized in an official USP-NF monograph (official from May 1st, 2017). The United States Pharmacopeia (USP) and The National Formulary are the public pharmacopeia standards for drug substances, dosage forms, excipients, compounded preparations, dietary supplements, and medical devices.
On November 08th, 2016, research firm Aegis Capital initiated a 'Buy' rating on the Company's stock. Register for free on Stock-Callers.com and get access to the latest PDF format report on MDXG at:
At the close, shares in Fremont, California headquartered WaferGen Bio-systems Inc. ended the day at $0.90, which was a decline of 1.21%. The stock recorded a trading volume of 333,695 shares, which was above its three months average volume of 217,150 shares. The Company's shares have advanced 23.14% in the last one month and 23.29% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 8.54% and 13.87%, respectively. Furthermore, shares of WaferGen Bio-systems, which develops, manufactures, and sells systems for single-cell analysis and clinical research in the US, Canada, Europe, and the Asia/Pacific, have an RSI of 58.98.
On November 15th, 2016, WaferGen Bio-systems announced that its stockholders have approved the adoption of the previously announced merger agreement by and among WaferGen, Takara Bio USA Holdings, Inc. and certain other parties thereto. The merger is expected to close in Q1 2017. Download your free research report on WGBS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA